Transition to KPL-387 Monotherapy Dosing & Administration Study

Recruiting now · Phase 2

Conditions studied: Recurrent Pericarditis, Heart Diseases, Pericarditis

In brief

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.

Key facts

Study ID

NCT07288216

Run by

Kiniksa Pharmaceuticals International, plc

People needed

80

Starts

2026-03-25

Expected to finish

2029-12-31

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigational Site 031 — Phoenix, Arizona, United States (enrolling)
• Investigational Site 014 — Los Angeles, California, United States (enrolling)
• Investigational Site 002 — Santa Monica, California, United States (enrolling)
• Investigational Site 039 — Jacksonville, Florida, United States (enrolling)
• Investigational Site 013 — Chicago, Illinois, United States (enrolling)
• Investigational Site 025 — Baltimore, Maryland, United States (enrolling)
• Investigational Site 028 — Rochester, Minnesota, United States (enrolling)
• Investigational Site 011 — New York, New York, United States (enrolling)
• Investigational Site 003 — New York, New York, United States (enrolling)
• Investigational Site 009 — Cincinnati, Ohio, United States (enrolling)
• Investigational Site 005 — Austin, Texas, United States (enrolling)
• Investigational Site 006 — Houston, Texas, United States (enrolling)
• Investigational Site 004 — Charlottesville, Virginia, United States (enrolling)
• Investigational Site 001 — Norfolk, Virginia, United States (enrolling)
• Investigational Site 008 — Richmond, Virginia, United States (enrolling)
• Investigational Site 010 — Ottawa, Ontario, Canada (enrolling)
• Investigational Site 027 — Paris, France (enrolling)
• Investigational Site 026 — Poitiers, France (enrolling)
• Investigational Site 032 — Toulouse, France (enrolling)
• Investigational Site 038 — Toulouse, France (enrolling)
• Investigational Site 035 — Athens, Greece (enrolling)
• Investigational Site 023 — Nea Ionia, Greece (enrolling)
• Investigational Site 024 — Voula, Greece (enrolling)
• Investigational Site 034 — Genoa, Italy (enrolling)
• Investigational Site 021 — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.